Neuroprogression in schizophrenia: Pathways underpinning clinical staging and therapeutic corollaries.
about
A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesisCognitive dysfunction in bipolar disorder and schizophrenia: a systematic review of meta-analysesOmega 3 Fatty Acids: Novel Neurotherapeutic Targets for Cognitive Dysfunction in Mood Disorders and Schizophrenia?Depression, Cytokine, and Cytokine by Treatment Interactions Modulate Gene Expression in Antipsychotic Naïve First Episode Psychosis.The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disordersRisk of Schizophrenia Increases After All Child and Adolescent Psychiatric Disorders: A Nationwide StudyPrediction of transition from ultra-high risk to first-episode psychosis using a probabilistic model combining history, clinical assessment and fatty-acid biomarkers.Association between DRD2 (rs1799732 and rs1801028) and ANKK1 (rs1800497) polymorphisms and schizophrenia: a meta-analysis.Chronic Peripheral Inflammation is Associated With Cognitive Impairment in Schizophrenia: Results From the Multicentric FACE-SZ Dataset.Adaptive Immunity in Schizophrenia: Functional Implications of T Cells in the Etiology, Course and Treatment.Physical Exercise Alleviates Health Defects, Symptoms, and Biomarkers in Schizophrenia Spectrum Disorder.Prevalence and correlates of suboptimal vitamin D status in people living with psychotic disorders: Data from the Australian Survey of High Impact Psychosis.Interactions Between Variation in Candidate Genes and Environmental Factors in the Etiology of Schizophrenia and Bipolar Disorder: a Systematic Review.Curcumin for neuropsychiatric disorders: a review of in vitro, animal and human studies.Systematic review and meta-analysis of the efficacy and safety of minocycline in schizophrenia.Functional Implications of the IL-23/IL-17 Immune Axis in Schizophrenia.Cognitive effects of adjunctive N-acetyl cysteine in psychosis.Potential drug targets and treatment of schizophrenia.Lack of Association Between Dopamine Beta-Hydroxylase (DBH) 19-bp Insertion/Deletion Polymorphism and Risk of Schizophrenia.Cognitive neuropsychological functioning in New Zealand Māori diagnosed with schizophrenia.Immuno-psychiatry: an agenda for clinical practice and innovative research.N-acetyl cysteine reverses bio-behavioural changes induced by prenatal inflammation, adolescent methamphetamine exposure and combined challenges.No association between dopamine D3 receptor gene Ser9Gly polymorphism (rs6280) and risk of schizophrenia: an updated meta-analysis.Changes in Tryptophan Catabolite (TRYCAT) Pathway Patterning Are Associated with Mild Impairments in Declarative Memory in Schizophrenia and Deficits in Semantic and Episodic Memory Coupled with Increased False-Memory Creation in Deficit SchizophrenPeripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics: meta-analysis and implications.Mitochondrial Dysfunction in Schizophrenia: Determination of Mitochondrial Respiratory Activity in a Two-Hit Mouse Model.Psychiatric disorders in primary care.Episodic memory and delayed recall are significantly more impaired in younger patients with deficit schizophrenia than in elderly patients with amnestic mild cognitive impairment.
P2860
Q26748778-C8E7E6E0-54F0-42C7-8124-B0D0B175307AQ26771515-AF0472FB-0C2E-493C-BC09-7B5E04D82D45Q26782982-36F22A6C-F008-485A-8879-A618CDC4ABE8Q34674152-0BA08F12-47E9-4237-B8C1-2A50F593EF49Q35246024-684E693A-D329-4182-9902-FEA236432F24Q35738964-35328E91-368D-4059-8B05-DF1AC2C63E67Q37307208-8C54C597-8FBF-4648-97D0-771D5691C18CQ38287758-AFDDE439-6641-43E0-8219-595B48EE6A78Q38392954-2E52CE2C-8234-4394-A0EF-79FF82A8B69AQ38544976-CAD2CB77-AF5D-4C3E-899C-42D2F7716772Q38547002-AB2DDA85-5959-4660-9274-B74CC3B396E3Q38614504-A0B9340C-34D5-4DE3-AD87-B0CA4FA830A2Q38640149-865094D7-EFB3-43A1-922F-2AEDBF684B9BQ38764276-F0FB6544-FFC6-4B92-A5FE-023218939243Q38970065-0383530B-1BEC-408F-AFC1-681974ECB385Q39024232-6918434F-C599-4EFE-87AC-1FAADC8866A6Q39147992-AF18C18C-543C-46F1-80A8-F53B53A9C2C2Q39206300-66CF9C71-85D1-4D00-8BDE-A96152FCE8A9Q40534601-3D1C42BA-FBFA-4D2C-A17A-99064CFE570FQ41192138-B030EDF6-5C09-4F32-9EC8-2190F03A0FA9Q42378870-5E8841C6-6549-443C-82E7-F82811D7D6DFQ46265873-8E8F49B3-6B45-4EF5-A8DD-5BA872710D65Q47162067-5D6137D6-1683-4299-9B04-9981E88BBC8BQ47628908-93373E93-FBA1-4426-A5EB-B564DF634EA2Q48507006-A3B335AA-ACA4-4765-A7AF-821C89472FA9Q50534987-0C4CDB0E-0E4B-450D-9EAF-3F368C23441AQ50641036-0872E6E9-2DB0-479F-B87C-31D9CA971AF2Q55280853-A5CDA182-AAEF-4D51-A562-A0FAC35AF8C5
P2860
Neuroprogression in schizophrenia: Pathways underpinning clinical staging and therapeutic corollaries.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Neuroprogression in schizophre ...... g and therapeutic corollaries.
@en
type
label
Neuroprogression in schizophre ...... g and therapeutic corollaries.
@en
prefLabel
Neuroprogression in schizophre ...... g and therapeutic corollaries.
@en
P2093
P2860
P356
P1476
Neuroprogression in schizophre ...... g and therapeutic corollaries.
@en
P2093
Justin Davis
Michael Maes
Steven Moylan
P2860
P304
P356
10.1177/0004867414533012
P577
2014-05-06T00:00:00Z